石蜡切片定量评估GBM胶原IV α链在FSGS与Alport基因变异患者中的应用
该研究开发了一种基于石蜡切片的免疫荧光成像方法,利用Airyscan共聚焦显微镜区分GBM中胶原α3α4α5(IV)与α1α1α2(IV)两层,并计算α5(IV):α1/2(IV)的平均荧光强度比和厚度比。11例对照样本两比值一致,而所有携带致病或可能致病COL4A变异患者的两比值均显著且明显降低,支持该方法有效性;进一步验证后可能有助于识别FSGS病变中可能携带致病COL4A变异、可从基因检测获益的患者亚组。
要点
- 石蜡切片免疫荧光可定量区分GBM胶原α3α4α5(IV)与α1α1α2(IV)两层。
- α5:α1/2强度比和厚度比在11例对照中一致,在致病COL4A变异患者中显著降低。
- 该方法经进一步验证后可能辅助识别FSGS病变中宜行基因检测的患者亚组。
核心结论
- 石蜡切片免疫荧光定量GBM胶原IV亚型丰度的方法有效,α5:α1/2强度比和厚度比在致病COL4A变异患者中显著降低。
研究设计与样本
- 研究在肾脏石蜡切片上采用Airyscan共聚焦显微镜进行胶原α5(IV)和α1/2(IV)免疫荧光成像,定量评估GBM胶原IV网络。
- 计算胶原α5(IV):α1/2(IV)平均荧光强度比和厚度比,以代表胶原α3α4α5(IV)相对α1α1α2(IV)的水平。
- 对照样本11例,并纳入携带致病或可能致病Alport COL4A变异的患者。
主要发现
- α5:α1/2强度比和厚度比在全部11例对照样本中可比。
- 两比值在所有携带致病或可能致病Alport COL4A变异的患者中均显著且明显降低。
临床怎么用
- 该定量免疫荧光方法经进一步验证后,可能用于识别FSGS病变中可能携带致病COL4A变异、可从基因检测获益的患者亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Focal segmental glomerulosclerosis (FSGS) lesions have been linked to variants in COL4A3/A4/A5 genes, which are also mutated in Alport syndrome. Although it could be useful for diagnosis, quantitative evaluation of glomerular basement membrane (GBM) type IV collagen (colIV) networks is not widely used to assess these patients. To do so, we developed immunofluorescence imaging for collagen α5(IV) and α1/2(IV) on kidney paraffin sections with Airyscan confocal microscopy that clearly distinguishes GBM collagen α3α4α5(IV) and α1α1α2(IV) as two distinct layers, allowing quantitative assessment of both colIV networks. The ratios of collagen α5(IV):α1/2(IV) mean fluorescence intensities (α5:α1/2 intensity ratios) and thicknesses (α5:α1/2 thickness ratios) were calculated to represent the levels of collagen α3α4α5(IV) relative to α1α1α2(IV). The α5:α1/2 intensity and thickness ratios were comparable across all 11 control samples, while both ratios were significantly and markedly decreased in all patients with pathogenic or likely pathogenic Alport COL4A variants, supporting validity of this approach. Thus, with further validation of this technique, quantitative measurement of GBM colIV subtype abundance by immunofluorescence, may potentially serve to identify the subgroup of patients with FSGS lesions likely to harbor pathogenic COL4A variants who could benefit from genetic testing.
引用
- Puapatanakul P, Isaranuwatchai S, Chanakul A, et al. Quantitative assessment of glomerular basement membrane collagen IV α chains in paraffin sections from patients with focal segmental glomerulosclerosis and Alport gene variants. Kidney Int. 2024. PMID: 38401706. doi:10.1016/j.kint.2024.01.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。